1Lattice Logo

Pharma and Biotech

Helping clients understand disease evolution and stakeholders’ perspectives to stay ahead of competition

Capabilities

What we do

18 capabilities
Capability

Disease landscaping and forecasting

 Disease landscaping and forecasting
Questions we answer
  • What is the key population afflicted with the disease?
  • How has the disease incidence changed over time?
  • What are the key symptoms and implications of the diseases?
  • What are the currently available treatments for the disease?
  • What is the current disease burden – direct costs, loss of productivity etc.?
  • Who are the key players in the treatment ecosystem of the disease?
  • How has their share or role evolved over time?
  • How is disease incidence, mortality / morbidity, customer LTV, market size and share expected to evolve over time?
Capability

Epidemiological studies

Epidemiological studies
Questions we answer
  • Which population is most affected by the disease?
  • How does the disease behavior vary across geographies, age-groups, ethnicity, environment etc.?
  • What is the risk of transmission of the disease in healthy population?
  • How magnified is the risk of disease infection in exposed population in comparison to unexposed population?
  • What is the distribution of the disease in a selected population group?
  • Which population is most vulnerable and should mandatorily be screened for the disease?
Capability

Pharma market tracking

Pharma market tracking
Questions we answer
  • Who are the market leaders across different therapeutic areas and geographies?
  • Which players have inherent advantages considering recent regulations?
  • How does the pipeline of key players look like?
  • When is the next patent cliff for generic manufacturers?
  • What are the expected strategies (M&A, fundraise, IPO, developed market entry) for key players?
  • What is the pace of NDA (New Drug Approval) / ANDA (Abbreviated New Drug Approval) for key players?
  • How has the share of key players changed in the last quarter, 6 months, 1 year, 5 years and 10 years?
Capability

Physician insights

 Physician insights
Questions we answer
  • What is the severity of the target disease in addressable population?
  • What is the rate of discovery and treatment for the disease?
  • Which treatments exist for the disease and what is their efficacy?
  • What is the degree of patient compliance for the disease treatment?
  • Does the treatment efficacy vary with demographics?
  • What is the typical patient journey in disease treatment?
  • What are the current white gaps in disease treatment?
Capability

Emerging therapies study

Emerging therapies study
Questions we answer
  • Which emerging therapies for the disease appear promising in terms of safety, efficacy, and cost?
  • What is the degree of willingness to accept / switch for the emerging therapy?
  • What are the proven, typical side effects of the therapy?
  • What is the intended plan of scale-up for the therapy?
  • What is the expected revenue stream initially and how is it expected to evolve over time?
  • What are the challenges associated with the launch and scale-up of emerging therapies?
Capability

Industry insights

Industry insights
Questions we answer
  • What new technologies are being adopted by the industry?
  • What are the most recent headwinds / tailwinds in the sector?
  • Which are the most profitable therapeutic areas currently?
  • What are the challenges currently faced by the pharma players?
  • How is digitization helping increase operational efficiencies?
  • When is the next patent cliff due?
  • What are the newest drugs / biologics approved by US FDA, EU CEP, other regulatory bodies?
  • What have been the most promising therapeutic areas in last 5-10 years?
Capability

Company and drug insights

Company and drug insights
Questions we answer
  • How much revenues have been recorded by the company / drug in the last financial period?
  • How does the unit economics of drug / company look like?
  • What is the company’s / drug’s supply chain?
  • What has been the historical journey of the company / drug?
  • Has the company / drug been involved in any major recalls or audit actions?
  • How strong is the company leadership and what is its vision?
  • Who are the key competitors in manufacturing of drug / biologic?
Capability

Product feasibility assessment

Product feasibility assessment
Questions we answer
  • Who is the target audience of the product?
  • Is the product substituting any existing product?
  • What is the product’s value proposition and differentiation with respect to competitors?
  • What is the expected degree of adoption or willingness to switch for the product?
  • What is the expected degree of success of the product launch?
  • Are there any regulatory clouds surrounding the product?
Capability

Patient needs and NPS

 Patient needs and NPS
Questions we answer
  • What are the key segments using the drug?
  • What is the NPS on the drug or therapy type?
  • What does the patient like about the drug?
  • What is the patient’s degree of choice of the product?
  • What doesn’t the patient like about the product – unpalatable dosage form, severe side-effects etc.?
  • What is the patient compliance on the drug?
  • How does NPS, feedback, KPC and degree of compliance vary across demographics?
Capability

Doctor NPS diagnostic

Doctor NPS diagnostic
Questions we answer
  • What are the key parameters influencing doctor’s NPS for the product?
  • What is doctor’s feedback on each of the parameters influencing NPS?
  • How does doctor’s NPS and feedback vary across patients’ demographics?
  • How can the manufacturer improve upon the NPS?
Capability

Pharmacovigilance study

 Pharmacovigilance study
Questions we answer
  • What is the performance of drug since market launch?
  • What is the degree of efficacy of the drug?
  • How does degree of efficacy vary across demographics, routes of administration, dosage form etc.?
  • Has there been any unlabeled harm observed in the patients?
  • What is the severity of the harm?
  • How does the unlabeled and unidentified harm vary across demographics?
  • How was the new issue missed during clinical trials reporting?
Capability

Real world and late stage research

Real world and late stage research
Questions we answer
  • How much revenues have been recorded by the company / drug in the last financial period?
  • How does the unit economics of drug / company look like?
  • What is the company’s / drug’s supply chain?
  • What has been the historical journey of the company / drug?
  • Has the company / drug been involved in any major recalls or audit actions?
  • How strong is the company leadership and what is its vision?
  • Who are the key competitors in manufacturing of drug / biologic?
Capability

Regulatory ecosystem

 Regulatory ecosystem
Questions we answer
  • What have been the most recent regulations put out by various pharmacopeia?
  • What are the implications of most recent regulations on the industry and patients?
  • Which parties will be impacted and what is the degree of impact on each of them?
  • How is competition responding to the regulations?
  • What are the local and international best practices in face of the regulations?
Capability

Channel partner NPS

 Channel partner NPS
Questions we answer
  • What is the channel partner’s portfolio with the client?
  • What is the partner’s NPS on each portfolio product?
  • How does partner’s NPS vary across channel type, margin size, geography and operating model?
  • What does the partner like / dislike about the product?
  • What are the key improvement areas for the client?
  • How does NPS, feedback, KPC and degree of compliance vary across demographics?
Capability

Sales force effectiveness

 Sales force effectiveness
Questions we answer
  • What is the sales force’s effectiveness in terms of standard industry parameters?
  • How does client’s sales force effectiveness benchmark with the competition on key parameters?
  • How does client’s sales organogram compare with that of the competition?
  • What are the local and international best practices to boost effectiveness?
  • How has the effectiveness changed over time?
  • How does effectiveness vary with product type, channel, geography and incentive schemes?
Capability

Cost benchmarking

Cost benchmarking
Questions we answer
  • How does client’s process cost fare with that of competition?
  • What is the structure and breakup of cumulative cost?
  • How do individual cost segments compare with competition?
  • What are the areas of improvement for the client with respect to competition?
  • Does client’s additional cost provide it a differentiation against competition?
  • What are the global best practices for cost optimization?
  • What are some of the short-term and long-term actions that can help optimise cost?
Capability

Micro-market expansion

Micro-market expansion
Questions we answer
  • What is the potential of select micro-market and what is client’s current share?
  • Has how client’s share in micro-market changed over time?
  • Is there potential for client’s growth in the select micro-market?
  • What would be client’s drivers of growth in the market?
  • What are client’s strengths and weaknesses with respect to competition?
  • What is the typical investment required to boost share?
  • What are some local and global best practices that can help client gain micro-market share?
Capability

Brand health diagnostic

Brand health diagnostic
Questions we answer
  • What is the degree of brand awareness with respect to competitors?
  • What are the key values associated with the brand?
  • What are the typical avenues for introducing brand to practitioners and patients?
  • What is the effectiveness of various channels for brand introduction?
  • How does brand awareness change with demographics and patient ailments?
  • How important is brand in the sale process?
  • What are some of the best practices to strengthen brand value?

Related Case Studies

View all
Customer sub-segmentation for insulin delivery devices
Pharma and BiotechApr 7, 2021

Customer sub-segmentation for insulin delivery devices

Objective

An Indian insulin manufacturer wanted to understand customer archetypes and KPC (Key Purchase Criteria) for various insulin delivery devices like syringes, insulin pens, jet injectors, inhalers and pens

Methodology

  • Conducted consumer survey (N = 600) and in-depth consumer interviews (N = 25) in 4 weeks across 40 cities (mix of metro, tier 1 & 2 cities) for different customer archetypes and KPC (based on household types, age groups, employment status, gender, severity, type (Type – I or Type – II) and duration of disease
  • Conducted trade interviews (N = 15) of distributors, stockists, pharmacists and retailers across product categories (syringes, insulin pens, inhalers and pumps) to understand KPC for customers and influencing power of trade in customer purchase
  • Conducted IDIs (N = 25) with medical practitioners, diabetologists and endocrinologists to understand recommendation process for delivery device and degree of choice for the patient
  • Carried out product and service benchmarking for key devices offered by key players to understand scope of differentiation for the client

Impact / Outcome

  • Client understood detailed insights on key consumer behaviour and preferences, key strengths and improvement areas for existing insulin delivery device players and process of recommendation by medical fraternity
Mapping online drug purchase process and estimating NPS for chronic disease patients
Pharma and BiotechApr 7, 2021

Mapping online drug purchase process and estimating NPS for chronic disease patients

Objective

A top e-pharmacy company in India wanted to benchmark its performance across product features and touchpoints against its peers

Methodology

  • Mapped customer journeys for offline and online drug purchase through customer interviews (N = 10) and mystery shopping?
  • Conducted consumer survey (N = 1,200) and in-depth customer interviews (N = 25) in 6 weeks across 25 cities (Metro, Tier-I and Tier-II) to develop customer archetypes and capture NPS for online drug purchase across geographies, age-groups, chronic disease types (diabetes, hypertension, migraine etc.)
  • Conducted competitor’s customer survey (N = 50) to understand detraction from client platform and identify areas of improvement
  • Understood key competitors’ strengths and weaknesses by elaborate secondary research
  • Deep-dived into performance and business journey of international players to find success analogs and sketch best practices for the client

Impact / Outcome

  • Client understood detailed insights on key consumer behaviour and preferences, key strengths and improvement areas for other e-pharmacy players and improvement areas to improve its NPS
Showing 12 of 4 case studies

Connect with our experts

Leadership profiles coming soon.